Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.77 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.77 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.77 |
| ▸ | PRKCG | P05129 | 3/20 | 0.77 |
| ▸ | PRKCB | P05771 | 3/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.77 |
| ▸ | PRKCA | P17252 | 3/20 | 0.77 |
| ▸ | PRKCH | P24723 | 3/20 | 0.77 |
| ▸ | PRKCI | P41743 | 3/20 | 0.77 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.77 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.77 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.77 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.77 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.77 |
| ▸ | PRKACA | P17612 | 2/20 | 0.77 |
| ▸ | PRKACG | P22612 | 2/20 | 0.77 |
| ▸ | PRKACB | P22694 | 2/20 | 0.77 |
| ▸ | CCR2 | P41597 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10985139 | 1.00 | ROCK2 (0.77) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL26584304 | 1.00 | ROCK2 (0.77) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| Hydrochloric Acid SCHEMBL9617961 | 0.99 | ROCK2 (0.77) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL10988523 | 0.99 | ROCK2 (0.79) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL29770053 | 0.94 | ROCK2 (0.77) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL4728462 | 0.88 | ROCK2 (0.65) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL7315948 | 0.87 | PRKD3 (0.74) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL14818897 | 0.87 | ROCK2 (0.67) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| Fasudil SCHEMBL6269832 | 0.87 | ROCK2 (1.00) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL2908265 | 0.87 | ROCK2 (0.67) | ROCK2ROCK1PRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201219-A1 | METHODS OF TREATING AGITATION AND OTHER DEMENTIA-ASSOCIATED BEHAVIORAL SYMPTOMS | WOOLSEY PHARMACEUTICALS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-8487004-B2 | Local treatment of neurofibromas | Nexgenix Pharmaceuticals, Inc. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120315298-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | NEXGENIX PHARMACEUTICALS, INC (US) | 2012-12-13 | — | — | US | disclosed |
| US-8211875-B2 | Local treatment of neurofibromas | Nexgenix Pharmaceuticals Inc (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| US-20110130388-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA | OSAKA UNIVERSITY (JP) | 2011-06-02 | — | — | US | disclosed |
| US-20110112053-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| US-20100048540-A1 | Heterocyclic N-Oxides as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112053-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | RHOA, LIPG, KDR | ROCK2 9/4885ROCK1 8/4885PRKD3 459/4885 |
| US-20100048540-A1 | Heterocyclic N-Oxides as Hypoxic Selective Protein Kinase Inhibitors | HIF1AN, HIF1A, HYOU1 | ROCK2 380/4885ROCK1 289/4885PRKD3 369/4885 |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | ROCK2 2882/4885ROCK1 2635/4885PRKD3 798/4885 |
| US-20110130388-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA | RHOA, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885PRKD3 217/4885 |
| US-20120315298-A1 | LOCAL TREATMENT OF NEUROFIBROMAS | VHL, NGF, S100B | ROCK2 3862/4885ROCK1 3674/4885PRKD3 3748/4885 |
| US-20230201219-A1 | METHODS OF TREATING AGITATION AND OTHER DEMENTIA-ASSOCIATED BEHAVIORAL SYMPTOMS | ROCK1, ROCK2, CIT | ROCK2 2/4885ROCK1 1/4885PRKD3 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.